View on Pubmed.gov 22363490 | View on doi.org 10.1371/journal...
Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia.
- Center for Microbial Genetics and Genomics, Northern Arizona University, Flagstaff, Arizona, United States of America.
Abstract
Burkholderia pseudomallei is a gram-negative bacterium that causes the serious human disease, melioidosis. There is no vaccine against melioidosis and it can be fatal if not treated with a specific antibiotic regimen, which typically includes the third-generation cephalosporin, ceftazidime (CAZ). There have been several resistance mechanisms described for B. pseudomallei, of which the best described are amino acid changes that alter substrate specificity in the highly conserved class A β-lactamase, PenA. In the current study, we sequenced penA from isolates sequentially derived from two melioidosis patients with wild-type (1.5 µg/mL) and, subsequently, resistant (16 or ≥256 µg/mL) CAZ phenotypes. We identified two single-nucleotide polymorphisms (SNPs) that directly increased CAZ hydrolysis. One SNP caused an amino acid substitution (C69Y) near the active site of PenA, whereas a second novel SNP was found within the penA promoter region. In both instances, the CAZ resistance phenotype corresponded directly with the SNP genotype. Interestingly, these SNPs appeared after infection and under selection from CAZ chemotherapy. Through heterologous cloning and expression, and subsequent allelic exchange in the native bacterium, we confirmed the role of penA in generating both low-level and high-level CAZ resistance in these clinical isolates. Similar to previous studies, the amino acid substitution altered substrate specificity to other β-lactams, suggesting a potential fitness cost associated with this mutation, a finding that could be exploited to improve therapeutic outcomes in patients harboring CAZ resistant B. pseudomallei. Our study is the first to functionally characterize CAZ resistance in clinical isolates of B. pseudomallei and to provide proven and clinically relevant signatures for monitoring the development of antibiotic resistance in this important pathogen.
References
J Clin Microbiol. 2005 Dec;43(12):6032-4
J Clin Microbiol. 2003 May;41(5):2068-79
J Clin Microbiol. 2009 May;47(5):1556-8
Res Microbiol. 1992 Oct;143(8):785-90
Cited by 94 citations (total)
Journal Article
Phylogeographic, genomic, and meropenem susceptibility analysis of Burkholderia ubonensis.
Electronic publication date October 3, 2017
Erin P Price [...] David M Wagner et al.
The bacterium Burkholderia ubonensis is commonly co-isolated from environmental specimens harbouring the melioidosis pathogen, Burkholderia pseudomallei. B. ubonensis has been...
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance.
Electronic publication date November 26, 2019
Sunisa Chirakul [...] Herbert P Schweizer et al.
Therapy of Burkholderia pseudomallei acute infections is largely limited to a few β-lactam antibiotics such as ceftazidime or meropenem. Although...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
Substances
- •